UK – NICE approval for Janssen’s Darzalex combination

Recommendation concerns routine use across the NHS as therapy for multiple myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex with bortezomib and dexamethasone (DVd) for treating multiple myeloma.

The therapy – also known as daratumumab – will be routinely used throughout the NHS among adults who have had a single previous treatment which included lenalidomide or when lenalidomide was not considered suitable as a second treatment…